Background Therapeutic advances have made the achievement of clear/almost clear skin possible for many patients
Introduction
Psoriasis, particularly in its more severe forms, imposes a heavy burden on patients. In addition to the effects of skin lesions on appearance, symptoms such as pain and itch are bothersome and interfere with daily activities. 1, 2 Lesions at certain locations, such as the palms or soles, can be especially disabling. 3 Psoriasis and its associated stigmatization exert harmful effects on multiple dimensions of health-related quality of life (QoL), including relationships, work productivity, ability to sleep and mental health. 4, 5 Psoriasis patients are at substantially increased risk of depression, anxiety and suicidality. 6, 7 Depression contributes to the increased mortality in psoriasis patients, which underscores its devastating psychosocial impact. 8 Psoriasis treatments have the potential to address many aspects of the disease. Psoriasis therapies are assessed foremost by their efficacy in ameliorating skin lesions. Clinical management guidelines, including European consensus treatment goals, define efficacy as ≥50% improvement from baseline in the Psoriasis Area and Severity Index (PASI 50 response). 9, 10 Patients in whom response fails to meet this threshold require modifications to their treatment. In recent years, an increasing array of options has become available for psoriasis patients in need of systemic agents, including biologic (inhibitors of tumour necrosis factor, interleukin [IL] 12/23, IL-17 or the IL-23 p19 subunit) and small-molecule (oral phosphodiesterase-4 inhibitor) therapies. For patients with access to the newer treatments, the expanded armamentarium, which now includes agents other than traditional systemic drugs (e.g. methotrexate, acitretin, cyclosporine A and fumaric acid esters), provides more opportunities for achieving satisfaction with the efficacy of their regimens. Given the advances in psoriasis treatment, higher response levels than PASI 50 are a realistic aspiration for efficacy in each patient; ≥90% PASI improvement (PASI 90 response) or a low absolute PASI (e.g. less than 2 or 3) have been proposed as feasible expectations. 11, 12 Although PASI 90 is determined relative to baseline psoriasis severity, and therefore will appear differently between individuals, a PASI 90 response provides a level of improvement that will correspond to clear or almost clear skin as perceived by the patient. 13 Psoriasis sufferers are often dissatisfied with their treatments but may accept inadequate efficacy because they do not know that clear or almost clear skin is attainable.
14 Little is known regarding patients' perception of the efficacy of psoriasis therapies and whether clearance would be possible. We conducted a worldwide survey of 8338 patients with moderate-to-severe plaque psoriasis from 31 countries to assess awareness of clear/ almost clear skin as a treatment goal, actual achievement of selfreported clear/almost clear skin in clinical practice, and the impact of clear/almost clear skin on patient lives.
Materials and methods

Survey design
This survey was developed in collaboration with a steering committee of medical experts that included dermatologists, general practitioners and representatives of psoriasis patient advocacy organizations (the US National Psoriasis Foundation and European EUROPSO). The steering committee advised on the selection of patient-reported outcome assessment tools to be used in the survey. The assessment instruments selected had all been previously validated and were used to capture the impact of clear/almost clear skin on multiple dimensions of patient life:
• Self-Administered Psoriasis Area and Severity Index (PASI):
A composite evaluation instrument to assess psoriasis severity, with subscores for erythema, induration, scaling and body surface affected (total score range of 0 to 72, with higher scores indicating more severe disease).
15
• Stanford Presenteeism Scale (version SPS-6): Consists of six questions that capture patient-perceived effects of disease on work productivity, with each item rated on a scale of 1 to 5.
16
• Medical Outcomes Study Sleep Scale: Measures sleep dimensions such as initiation, quantity, maintenance and somnolence.
17
• World Health Organization Well-Being Index: A 5-item questionnaire for the assessment of psychological wellbeing. 18 The survey, which could be conducted online or in face-toface interviews, consisted largely of multiple-choice questions and could be completed in approximately 20 min. To collect data on psoriasis patients worldwide, the instrument was translated into 32 languages for use in 31 countries. Psoriasis patient advocacy organizations reviewed the survey to ensure ease of use and understanding.
Patient sample
Participants were recruited from 31 countries via 25 psoriasis patient organizations and the market research company GfK (Nuremberg, Germany) and screened for eligibility (see Appendix S1 for countries/patient organizations). Patient advocacy organizations distributed the survey hyperlink via different channels, including Twitter, Facebook and online/offline newsletters.
Inclusion criteria
Participants had to be ≥18 years old and currently have plaque psoriasis that was diagnosed by a general practitioner, dermatologist, rheumatologist, allergist or other medical professional. Moderate-to-severe psoriasis was defined using self-assessed PASI. For this survey, moderate-to-severe psoriasis was defined as either: (i) PASI ≥10, which is a standard definition of moderate-to-severe psoriasis; 19 or (ii) PASI >5 to <10 with psoriasis affecting sensitive and/or prominent body parts: face, palms, hands, fingers, genitals, soles of feet or nails. The second definition was introduced following endorsement by expert dermatologists on the survey steering committee and after approximately 40% enrolment. The second definition accounts for the potentially debilitating impact of psoriasis located on certain body parts.
Ethical conduct of the survey
Patient informed consent was obtained at the beginning of the survey. As this was a non-interventional study that invited members of the public to participate, this study is exempt from institutional review board approval.
Results
Survey conduct and sample
The study period for completion of the Clear About Psoriasis survey was from October 2015 to March 2016. Patients were recruited from 31 countries in Asia, Australia, Europe, North America and South America. A total of 398 230 patients were recruited; these individuals were directed to the landing page of the survey website. Approximately 154 000 began actively filling out the survey and were screened for eligibility during the first 19 questions. Of the screened population, 8338 met the eligibility criteria and participated in the survey. Most of the patients screened were ineligible because they did not have plaque psoriasis or did not meet the self-assessed PASI criteria. Participant demographic and clinical characteristics are shown in Table 1 .
Findings
When participants were asked for a subjective impression of whether their current psoriasis treatment provides clear or almost clear skin, 57% (n = 4733) answered that they had not reached this goal with current therapy, and 43% (n = 3605) replied that they had. Participants were also asked whether they were satisfied with their current psoriasis therapy: 56% were satisfied, 24% were uncertain, and 20% were dissatisfied ( Fig. 1) . A correlation was evident between treatment satisfaction and having clear/almost clear skin: respondents who were satisfied with their current therapy were more likely to have clear/almost clear skin, whereas respondents dissatisfied with treatment were disproportionately more likely to have not achieved clear/almost clear skin. In a comparison of medication use between patients with and without self-reported clear/almost clear skin, higher proportions of patients with clear/almost clear skin were using oral systemics or injectable biologics, whereas a higher proportion of patients without clear/almost clear skin reported using prescription or non-prescription topical therapies (Fig. 2) . Most respondents without self-reported clear/almost clear skin were not aware that this is a realistic treatment goal: 56% disagreed with the statement that it would be possible to achieve clear/almost clear skin in future. Similarly, respondents who had already achieved self-reported clear/almost clear skin with their current treatment were asked to report retrospectively whether they had believed that this treatment goal was attainable, prior to actually achieving it. Fifty-three percent had not believed that clear/ almost clear skin was possible before actually experiencing it. Other 3%
Family status
Married 55%
Single 25%
In a relationship 16%
Other 4%
Mean PASI 14.3
PASI ≥10 68%
PASI >5 to <10 32%
Psoriatic arthritis* 51% *Self-reported and not a medically confirmed diagnosis.
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Among patients who had self-reported clear/almost clear skin, nearly three quarters started their current, efficacious therapy >1 year after diagnosis, and 28% were prescribed their current therapy >5 years after diagnosis (Fig. 3) . On average, patients had required four different treatments and needed to see three different medical professionals before achieving clear/almost clear skin.
A large majority of participants (84%) reported experiences of discrimination and/or humiliation in daily life, which highlights the importance of effective symptom control (Fig. 4) . The minority (16%) who did not report negative experiences had less psoriasis involvement (PASI >5 to <10 vs. PASI ≥10) and were more likely to be male, to be older and to have achieved clear/ almost clear skin. Although not a form of social discrimination, the additional burden of housework resulting from flaking skin was cited by many respondents (37%) as a negative impact of psoriasis on daily life.
Feelings of isolation and shame were common. Many respondents agreed with the statements 'I feel self-conscious about my skin' (51%), psoriasis 'makes me feel unattractive' (44%), 'I feel ashamed about my skin' (40%) and psoriasis 'makes me feel less confident about myself' (39%).
Psoriasis exerted a negative impact on work performance. Among the employed respondents (n = 5537), 42% needed ≥1 day off from work in the previous 6 months due to psoriasis, and 16% needed ≥10 days off (Fig. 5a ). Among patients who took ≥1 day off over 6 months, the mean number of days taken was 10.1. Fifty-four percent (n = 4505) of all respondents believed that psoriasis had impacted their professional lives (Fig. 5b) . In this subgroup, 38% stated that they lost productivity due to psoriasis-related itching, 30% were not fully productive due to pain, and 11% had to quit a job due to psoriasis. Forty-two percent of all respondents indicated that itch reduction was an important treatment goal for them.
Forty-three percent of all participants believed that psoriasis had affected past or current relationships. One of two participants agreed with the statement 'I avoid having sex/intimate relationships with people because of my psoriasis'. Large proportions also agreed with the statements 'I can't stand the thought of someone seeing my skin' (40%), 'I feel inadequate as a spouse or partner' (33%), 'I can't stand the thought of someone touching my skin' (27%), and 'I avoid dating because I am ashamed of my psoriasis' (26%).
Nearly one-third (32%) of respondents reported that their disease made them depressed. Participants voiced feelings of despair and loneliness and acknowledged suicidal thoughts. Although participants were not asked directly about suicidal ideation, a review of the open-ended responses from English-speaking Patient attitudes on skin clearance in psoriasis participants found that it was reported by 11 respondents. The true number of respondents who had experienced suicidal thoughts is likely to have been higher. In addition to effects on mood, a large proportion of all respondents (61%) reported psoriasis-related insomnia, and 26% slept only 3-5 h per night. Subjects who had not achieved clear/almost clear skin believed that doing so would improve their ability to participate in a range of life activities (Fig. 6 ).
Discussion
While patient perceptions of and attitudes about psoriasis and its treatment are considered increasingly paramount in managing the disease, few studies have systematically elicited patients' perspectives on a large scale. [20] [21] [22] [23] [24] [25] The study reported here took an innovative approach of evaluating broad aspects of patient experience, encompassing questions on symptom severity, treatment efficacy, and the impact of psoriasis on aspects of healthrelated QoL, such as sleep, work productivity and relationships. The survey extended globally, recruiting 8338 participants from 31 countries. A key finding is that the majority (57%) of patients with extensive disease have still not achieved self-reported clear or almost clear skin. Among respondents who had not achieved clear/almost clear skin with their current treatment, most (53-56%) were not even aware that this is a realistic aspiration.
Among patients who considered themselves clear/almost clear, 28% had not started an effective psoriasis treatment until >5 years after diagnosis. This statistic underscores the variability in psoriasis care delivery among healthcare providers and potential knowledge or access gaps that need to be addressed. The difficulty that patients reported in finding effective therapy is consistent with recent data on the suboptimal treatment of psoriasis. Studies have indicated that 20-32% of patients with moderate-to-severe psoriasis are not receiving any therapy, 26, 27 and undertreatment is common, with substantial proportions of moderate (19-30%) and severe (22-33%) psoriasis patients receiving topical treatments only. 14, 27 High proportions of survey respondents indicated that their disease resulted in discrimination or humiliation in daily life and negative consequences for work and personal relationships. Such experiences were associated with feelings of shame and isolation. Negative feelings and experiences would be expected to carry an elevated mental health risk; indeed, nearly one-third of respondents reported that their psoriasis made them depressed.
Among respondents overall, 56% reported satisfaction with their current treatment. Earlier surveys found the rate of treatment satisfaction (i.e. proportion of respondents who were 'very satisfied') to be <50%. 20, 21 Although comparisons across different surveys should be made with caution, these data suggest that recent advances in psoriasis therapeutics may be improving patient impressions of treatment. Some (17%) respondents who reported clear/almost clear skin were still not satisfied with treatment. Inadequate understanding of the high level of improvement required for clinically defined clear/almost clear skin, risk of relapse, and persistent anxiety and/or depression seem likely reasons for this result. The continued dissatisfaction may also point to a role for cumulative life course impairment (CLCI) in establishing enduringly negative feelings. CLCI in psoriasis refers to the permanently life-altering effects of psoriasis and its stigmatization in limiting opportunities and closing off aspirations of an educational, professional or personal nature. 28, 29 Barriers to effective systemic psoriasis therapy are well-documented. 30 Earlier and more effective treatment of psoriasis may have long-lasting benefits throughout patient lives. Although half of the respondents stated that they avoided sex/ intimate relationships because of their psoriasis, 71% reported being married or in a relationship, a proportion that was largely consistent across all geographic regions of the survey (data not shown). The percentage of respondents who were partnered, although seemingly high, was similar to that reported for psoriasis patients in the US National Health and Nutrition Examination Survey (69%) and a study conducted in Spain and Portugal (66%). 31, 32 The questions on intimacy in this survey captured respondent perceptions on how the disease affected their relationships, perceptions that may not necessarily align with actual relationship status. The loss of work time and productivity reported by psoriasis sufferers was substantial. Respondents who needed time off from work due to psoriasis reported taking an average of 10 sick days in the previous 6 months. Based on the mean hourly US wage of $23.23 (2015 dollars), this time away would translate into a yearly cost of sick leave >$3700 per person. 33 A score of 0 or 1 on the various physician's global assessment instruments for psoriasis severity is often taken to mean clear/almost clear skin, yet many patients who are assigned these scores do not meet PASI 90 criteria. 34 Given that a PASI 90 response to treatment is associated with substantially greater improvement in disease-related QoL than lesser levels of PASI response, 13 this survey may have failed to capture the full implications of clinically defined clear/almost clear skin for patient lives. Survey eligibility criteria included a diagnosis of psoriasis by a medical professional, but diagnostic practices may have differed substantially by geographic region and/or medical specialty. In particular, the accurate diagnosis of the group of patients with limited extent disease was likely to have been difficult for nonspecialists, potentially leading to the inadvertent inclusion of respondents with non-psoriasis conditions, such as chronic hand eczema or fungal infection. As with all surveys, other limitations include the potential for selection bias, recall bias and ambiguity/misinterpretation of the questions. In particular, for the question on how long after diagnosis it took to start effective therapy, the possible answers were not mutually exclusive (<1 year, >1 year, >2 years, >5 years). Respondents who required >5 years to initiate effective therapy may have selected one of three different answers, thereby potentially yielding an underestimate of the true amount of time.
The survey nonetheless provides robust findings on the importance of attaining clear/almost clear skin in psoriasis and the persistence of inadequate treatment, even with the availability of multiple therapeutic options. PASI 90 appears to be an increasingly realistic expectation, but self-reported achievement of clear/almost clear skin in real-world settings occurs in only a minority of patients, in a context in which the undertreatment of psoriasis is still common. Sustained achievement of high skin clearance has the potential to improve severe QoL deficits in psoriasis and open a wider horizon of life experiences to patients.
